The data showed that the levels of Srebp1 in nuclear and cytoplasm were increased in the liver of MCD-fed NASH mice and reduced by rifaximin treatment (Supplementary Figure S1D). Here, SREBF1 is linked to metabolic dysfunction-associated steatohepatitis.